208 related articles for article (PubMed ID: 36309225)
21. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease.
Theken KN; Schuck RN; Edin ML; Tran B; Ellis K; Bass A; Lih FB; Tomer KB; Poloyac SM; Wu MC; Hinderliter AL; Zeldin DC; Stouffer GA; Lee CR
Atherosclerosis; 2012 Jun; 222(2):530-6. PubMed ID: 22503544
[TBL] [Abstract][Full Text] [Related]
22. Acute mercury toxicity modulates cytochrome P450, soluble epoxide hydrolase and their associated arachidonic acid metabolites in C57Bl/6 mouse heart.
Amara IE; Elshenawy OH; Abdelrady M; El-Kadi AO
Toxicol Lett; 2014 Apr; 226(1):53-62. PubMed ID: 24472606
[TBL] [Abstract][Full Text] [Related]
23. Role of cytochrome P450-epoxygenase and soluble epoxide hydrolase in the regulation of vascular response.
Nayeem MA; Geldenhuys WJ; Hanif A
Adv Pharmacol; 2023; 97():37-131. PubMed ID: 37236764
[TBL] [Abstract][Full Text] [Related]
24. Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function.
Imig JD
Adv Pharmacol; 2016; 77():105-41. PubMed ID: 27451096
[TBL] [Abstract][Full Text] [Related]
25. Elevated 14,15- epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer.
Wei X; Zhang D; Dou X; Niu N; Huang W; Bai J; Zhang G
BMC Cancer; 2014 Nov; 14():841. PubMed ID: 25406731
[TBL] [Abstract][Full Text] [Related]
26. Increased epoxyeicosatrienoic acids may be part of a protective mechanism in human ulcerative colitis, with increased CYP2J2 and reduced soluble epoxide hydrolase expression.
Qiu YE; Qin J; Luo Y; Qin SL; Mu YF; Cun R; Jiang HL; Chen JJ; Yu MH; Zhong M
Prostaglandins Other Lipid Mediat; 2018 May; 136():9-14. PubMed ID: 29580941
[TBL] [Abstract][Full Text] [Related]
27. Epoxyeicosatrienoic Acids Inhibit the Activation of Murine Fibroblasts by Blocking the TGF-
Tao JH; Liu T; Zhang CY; Zu C; Yang HH; Liu YB; Yang JT; Zhou Y; Guan CX
Oxid Med Cell Longev; 2022; 2022():7265486. PubMed ID: 36275905
[TBL] [Abstract][Full Text] [Related]
28. The Role of Epoxyeicosatrienoic Acids in Cardiac Remodeling.
Lai J; Chen C
Front Physiol; 2021; 12():642470. PubMed ID: 33716791
[TBL] [Abstract][Full Text] [Related]
29. Targeting epoxides for organ damage in hypertension.
Imig JD
J Cardiovasc Pharmacol; 2010 Oct; 56(4):329-35. PubMed ID: 20531214
[TBL] [Abstract][Full Text] [Related]
30. Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids.
Shahabi P; Siest G; Visvikis-siest S
Drug Metab Rev; 2014 Feb; 46(1):33-56. PubMed ID: 24040964
[TBL] [Abstract][Full Text] [Related]
31. Epoxyeicosatrienoic acids and soluble epoxide hydrolase in physiology and diseases of the central nervous system.
Kuo YM; Lee YH
Chin J Physiol; 2022; 65(1):1-11. PubMed ID: 35229747
[TBL] [Abstract][Full Text] [Related]
32. Epoxides and soluble epoxide hydrolase in cardiovascular physiology.
Imig JD
Physiol Rev; 2012 Jan; 92(1):101-30. PubMed ID: 22298653
[TBL] [Abstract][Full Text] [Related]
33. Renal Ischemia/Reperfusion Injury in Soluble Epoxide Hydrolase-Deficient Mice.
Zhu Y; Blum M; Hoff U; Wesser T; Fechner M; Westphal C; Gürgen D; Catar RA; Philippe A; Wu K; Bubalo G; Rothe M; Weldon SM; Dragun D; Schunck WH
PLoS One; 2016; 11(1):e0145645. PubMed ID: 26727266
[TBL] [Abstract][Full Text] [Related]
34. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha.
Ng VY; Huang Y; Reddy LM; Falck JR; Lin ET; Kroetz DL
Drug Metab Dispos; 2007 Jul; 35(7):1126-34. PubMed ID: 17431031
[TBL] [Abstract][Full Text] [Related]
35. Preservation of epoxyeicosatrienoic acid bioavailability prevents renal allograft dysfunction and cardiovascular alterations in kidney transplant recipients.
Duflot T; Laurent C; Soudey A; Fonrose X; Hamzaoui M; Iacob M; Bertrand D; Favre J; Etienne I; Roche C; Coquerel D; Le Besnerais M; Louhichi S; Tarlet T; Li D; Brunel V; Morisseau C; Richard V; Joannidès R; Stanke-Labesque F; Lamoureux F; Guerrot D; Bellien J
Sci Rep; 2021 Feb; 11(1):3739. PubMed ID: 33580125
[TBL] [Abstract][Full Text] [Related]
36. The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease.
Schuck RN; Zha W; Edin ML; Gruzdev A; Vendrov KC; Miller TM; Xu Z; Lih FB; DeGraff LM; Tomer KB; Jones HM; Makowski L; Huang L; Poloyac SM; Zeldin DC; Lee CR
PLoS One; 2014; 9(10):e110162. PubMed ID: 25310404
[TBL] [Abstract][Full Text] [Related]
37. A novel role for P450 eicosanoids in the neurogenic control of cerebral blood flow in the rat.
Iliff JJ; Close LN; Selden NR; Alkayed NJ
Exp Physiol; 2007 Jul; 92(4):653-8. PubMed ID: 17639071
[TBL] [Abstract][Full Text] [Related]
38. Glimepiride, a novel soluble epoxide hydrolase inhibitor, protects against heart failure via increasing epoxyeicosatrienoic acids.
Zhao C; Jiang X; Peng L; Zhang Y; Li H; Zhang Q; Wang Y; Yang F; Wu J; Wen Z; He Z; Shen J; Chen C; Wang DW
J Mol Cell Cardiol; 2023 Dec; 185():13-25. PubMed ID: 37871528
[TBL] [Abstract][Full Text] [Related]
39. Soluble Epoxide Hydrolase as a Potential Key Factor for Human Prenatal Development.
Cizkova K; Rajdova A; Ehrmann J
Cells Tissues Organs; 2016; 201(4):277-86. PubMed ID: 27144772
[TBL] [Abstract][Full Text] [Related]
40. Epoxyeicosanoids as mediators of neurogenic vasodilation in cerebral vessels.
Iliff JJ; Wang R; Zeldin DC; Alkayed NJ
Am J Physiol Heart Circ Physiol; 2009 May; 296(5):H1352-63. PubMed ID: 19304946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
